CoChat
Sign Up
Cited by 205Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and Management

Lupus anticoagulants and the risk of a first episode of deep venous thrombosis

Open access
DE GROOT, P. G, LUTTERS, B., DERKSEN, R.H.W.M., LISMAN, T., MEIJERS, J.C.M., ROSENDAAL, F.R.·2005·Journal of Thrombosis and Haemostasis
DOI 10.1111/j.1538-7836.2005.01485.x
Open this paper in CoChat — free account

Abstract

We have determined lupus anticoagulants, anti-beta2 glycoprotein I (beta2GPI) and antiprothrombin antibodies in the Leiden Thrombophilia Study, a population-based case-control study designed to determine risk factors for deep venous thrombosis (DVT). Lupus anticoagulant (LAC) was measured in 473 patients and 472 control subjects. Four control subjects (0.9%) and 14 patients (3.1%) had a positive LAC, resulting in a 3.6-fold increased risk [odds ratio (OR) 3.6, 95% CI: 1.2-10.9]. Of the total population, 49 were positive for anti-beta2GPI antibodies: 15 controls (3.4%) and 34 patients (7.5%), implying a 2.4-fold increased risk (95% CI: 1.3-4.2). Antiprothrombin antibodies were present in 114 subjects: 48 controls (11.0%) and 66 cases (14.6%) with an OR of 1.4 (95% CI: 1.0-2.1). When LAC was considered in the co-presence of antiprothrombin or anti-beta2GPI antibodies the OR increased to 10.1 (95% CI: 1.3-79.8). A LAC without a positive anti-beta2GPI or antiprothrombin test was not associated with a risk for DVT (OR 1.3, 95% CI: 0.3-6.0). This study demonstrates that the presence of LAC, anti-beta2GPI antibodies and antiprothrombin antibodies are risk factors for DVT in a general population. The strongest association holds for the combination LAC and the presence of anti-beta2GPI or antiprothrombin antibodies.

Integrity signals

Registry

Crossref · 10.1111/j.1538-7836.2005.01485.x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Patients with lupus anticoagulant (LA) are at increased risk of arterial and venous thrombosis.

    “Autoantibodies directed against phospholipid-binding plasma proteins (also known as antiphospholipid (aPL) antibodies), detected through coagulation assays such as the lupus anticoagulant (LA) and through immunoassays such as anticardiolipin (aCL) or anti-β2-glycoprotein I (aβ2-GPI), confer an increased risk of arterial and venous thrombosis [1].”

    From Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant (2017) · cites this paper as [1]

  • In the Leiden thrombophilia case-control study, lupus anticoagulant positivity in the absence of anti-β2GPI or antiprothrombin antibodies was not associated with an increased risk of deep vein thrombosis (odds ratio 1.3; 95% CI, 0.3-6.0).

    “LA positivity in the absence of anti-␤ 2 GPI or antiprothrombin antibodies was not associated with an augmented risk for deep vein thrombosis (odds ratio ϭ 1.3; 95% CI, 0.3-6.0)”

    From Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study (2011) · cites this paper as [24]

  • In a population-based case-control study, LA with the concomitant positivity of anti-β2-glycoprotein I or anti-PT showed the highest thrombosis risk.

    “In a population-based case–control study, LA with the concomitant positivity of anti-β2-glycoprotein I or anti-PT showed the highest thrombosis risk.”

    From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [32]

  • In a population-based case-control study, single LA positivity without anti-β2-glycoprotein I or anti-PT did not carry an increased risk for DVT.

    “In contrast, single LA positivity without anti-β2-glycoprotein I or anti-PT did not carry an increased risk for DVT [32].”

    From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [32]

  • Retrospective, case-control and cross-sectional studies with different designs, patient selection criteria, aPL profiles and risk factors have produced contradictory results.

    “Retrospective, [1][2][3][4] case-control [5][6][7][8][9][10][11][12] and cross-sectional 13,14 studies with different designs, patient selection criteria, aPL profiles and risk factors have produced contradictory results.”

    From Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. (2011) · cites this paper as [5]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
DE GROOT, P. G., LUTTERS, B., DERKSEN, R. H. W. M., LISMAN, T., MEIJERS, J. C. M., & ROSENDAAL, F. R.
Affiliations
  • University Medical Center Utrecht (NL)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Leiden University Medical Center (NL)
ORCID
Venue
Journal of Thrombosis and Haemostasis
Publisher
Elsevier BV
Published
2005-09
Volume
3
Issue
9
Pages
1993-1997
ISSN
1538-7836 (ISSN-L)
DOI
10.1111/j.1538-7836.2005.01485.x
OpenAlex
W2111238248
Cited by
205
References
22
Citations by year
2026: 7 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 10 · 2019: 9 · 2018: 11 · 2017: 15 · 2016: 15 · 2015: 10 · 2014: 14 · 2013: 10 · 2012: 13
FWCI
7.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Thrombosis and Haemostasis (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Leiden Repository (Leiden University) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
ZonMw
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
lupus anticoagulant, deep vein thrombosis, anti-beta2-glycoprotein I antibodies, anti-prothrombin antibodies, thrombophilia, thrombosis risk factors, autoantibodies
MeSH terms
Adolescent, Adult, Aged, Autoantibodies, Female, Glycoproteins, Humans, Male, Middle Aged, Prothrombin, Risk Factors, Odds Ratio, Case-Control Studies, Lupus Coagulation Inhibitor, Venous Thrombosis, beta 2-Glycoprotein I

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review